

Some types of developing bio artificial devices include: the Extracorporeal Liver Assisting Device (ELAD), HepatAssist, Modular Extracorporeal Liver Support (MELS), and the Amsterdam Medical Center Bioartificial Liver (AMC-BAL).

While the artificial liver dialysis devices include :-
Molecular Adsorbent Reticulating system (MARS) , Single Pass Albumin Dialysis (SPAD) , Prometheus system.

The real need for these complicated devices in patients with fulminant hepatic failure is to prevent or reverse the potentially fatal cerebral edema that occurs in this setting .

In fact , artificial livers Studies are still ongoing to determine the beneficial effects and its future role in the management of liver failure. Survival will be the ultimate outcome parameter for these studies of the artificial liver.

References

Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. *Arch Intern Med* 1979;139:667-9.

Aggarwal R, Shahi H, Naik S, et al. Evidence in favour of high infection rate with hepatitis E virus among young children in India. *J Hepatol.* Jun 1997;26(6):1425-6.

Akriviadis E, Botla R, Briggs Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterology.* Dec 2000;119(6):1637-48.

Allen J, Hassanein T, Bhatia S (2001). "Advances in bioartificial liver devices". *Hepatology* **34** (3): 447–55.

Als-Nielsen B, Gluud L, Gluud C (2004). "Nonabsorbable disaccharides for hepatic encephalopathy". *Cochrane Database Syst Rev*: CD003044. doi:10.1002/14651858.CD003044.pub2. PMID 15106187.

Als-Nielsen B, Gluud LL, Gluud C (2004). "Benzodiazepine receptor antagonists for hepatic encephalopathy". *Cochrane database of systematic reviews (Online)* (2): CD002798. doi:10.1002/14651858.CD002798.pub2. PMID 15106178.

Alter MJ. Epidemiology of hepatitis C. *Hepatology*. Sep 1997;26(3 Suppl 1):62S-65S. *Ann Hepatol* 5 (4): 281–8. PMID 17151582.

Am Fam Physician 2006;74:756-62,781. Copyright © 2006 American Academy of Family Physicians.)

American College of Radiology, Expert Panel on Gastrointestinal Imaging. Liver lesion characterization. Reston, Va.: American College of Radiology, 2002.

American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. *Gastroenterology* 2002;123:1702-4.

Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology*. Jun 1999;29(6):1690-7.

Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. *Hepatology*. Jan 1996;23(1):164-76.

Artz SA, Paes IC, Faloon WW (1966). "Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy". *Gastroenterology* 51 (6): 1046–53. PMID 5958605.

Ash SE., Carr DJ, Blake DE, RairiierJB, Demetriou AA, RozgaJ. Effect of sorbent based dialytic therapy with the BioLogic-DT on an experimental model of hepatic failure. *ASAIOJ* 1993; 39: M657-80.

Ash SR ,Blake DE, Carr DJ, et al .Clinical effects of adsorbent suspension dialysis system in treatment of hepatic coma (the biologic – DT).*Int J Artificial Organs* [1992;15:151-61. Pub Med]

Ash, SE., Steczkoj, Knab WE., Blake DE, Karr DJ, Harker KD, Levy H. Push-pull sorbent based pheresis and hemodiabsorption in treatment of hepatic failure: Preliminary results of a clinical trial with the BioLogic-DTPF system. *Therapeutic Apheresis*, 2000; 4: 21 8-228.

Bacon B, Regev A, Ghalib R. Use of daily interferon alfacon-1 (Infergen, CIFn) plus ribavirin in patients infected with hepatitis C who are nonresponders to previous pegylated interferon plus RBV therapy: 24-week data from the DIRECT trial. *Hepatology*. 2006;44:698A.

Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K (2007). "Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations". *Am J Gastroenterol* **102** (9): 1903–09. doi:10.1111/j.1572-0241.2007.01424.x. PMID 17640323.

Bajaj JS, Saeian K, Verber MD, *et al* (2007). "Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy". *Am. J. Gastroenterol.* **102** (4): 754–60. doi:10.1111/j.1572-0241.2007.01048.x. PMID 17222319.

Barnardo DE, Baldus WP, Maher FT. Effects of dopamine on renal function in patients with cirrhosis. *Gastroenterology*. Apr 1970;58(4):524-31.

Bass NM. Drug-Induced Liver Disease. In: Friedman S, McQuaid K, Grendell, J, eds. *Current Diagnosis and Treatment in Gastroenterology*. 2nd ed. New York, NY: McGraw-Hill Professional; 2003. 664-79.

Bataller R, Sort P, Gines P, Arroyo V. Hepatorenal syndrome: definition, pathophysiology, clinical features and management. *Kidney Int Suppl.* May 1998;66:S47-53.

Bateman J, Chapman RD, Simpson D. Possible toxicity of herbal remedies. *Scott Med J.* Feb 1998;43(1):7-15.

Batt AM, Ferrari L. Manifestations of chemically induced liver damage. *Clin Chem.* Dec 1995;41(12 Pt 2):1882-7.

Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. *Am J Surg Pathol.* Dec 1995;19(12):1409-17.

Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled

randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. *Lancet*. Dec 2000;356(9248):2139-43.

Benett and Plum .(1994). Diseases of the liver, bile bladder and bile ducts, hepatic metabolism in liver disease, Cecil textbook of medicine, 20th edition .Partxii;114

Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. *Lancet*. Feb 2002;359(9306):558-63.

Bernal W. Intensive care support therapy. *Liver Transpl*. Sep 2003;9(9):S15-7.

Bernau, *et al*. Fulminant and subfulminant liver failure: definitions and causes, Semin, Liver dis. 1986, 6 (2) 98.

Bernau, Goudeaua, Povnardt *et al*. Multivariate analysis of prognostic factors in fithninant hepatitis B. Hepatology 1986.

Bernuau et al and O'Grady *et al*, Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94.

Beyeler C, Reichen J, Thomann SR, et al. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. *Br J Rheumatol*. Mar 1997;36(3):338-44.

Bismuth H, Samuel D, Castaing D, et al. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996; 16: 4 15-25.

Blei AT, Córdoba J (2001). "Hepatic Encephalopathy". *Am. J. Gastroenterol.* **96** (7): 1968–76. doi:10.1111/j.1572-0241.2001.03964.x. PMID 11467622.

Blei AT. The pathophysiology of brain edema in acute liver failure. *Neurochem Int*. Jul 2005;47(1-2):71-7.

Blum RS. Legal considerations in off-label medication prescribing. *Arch Intern Med.* Aug 2002;162(15):1777-9.

Bolego C, Baetta R, Bellosta S. Safety considerations for statins. *Curr Opin Lipidol.* Dec 2002;13(6):637-44.

Bolton JS, Bowen JC. Biliary sclerosis associated with hepatic artery infusion of floxuridine. *Surgery.* Jan 1986;99(1):119-22.

Bucci L, Palmieri GC (1993). "Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium-to severe-degree hepatic encephalopathy". *Current medical research and opinion* 13 (2): 109–18. PMID 8325041.

BuresJ, Buresova O, HustonJP. Innate and motivate behaviour. Amsterdam: Elsevier, 1957: 37-45.

Caldwell SH et al: Recombinant factor VII (rVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. *Hepatology*2004;39:592.

Canalese J, Gimson AE, David C, Mellon PJ, Davis NT, Williams R. Controlled trials of dexamethasone and mannitol for the cerebral edema of fulminant hepatic failure, *Gut.* 1982; 23(7):625-9.

Cardenas A et al: Review article: hepatic hydrothorax. *Aliment Pharmacol Ther* 2004;20:271.

Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. *Am J Gastroenterol.* Feb 2005;100(2):460-7.

Carithers RL: Liver transplantation. American Association for the Study of Liver Diseases. *Liver Transpl* 2000;6:122-135. This evidenced-based consensus guideline developed by the Standards of Practice Committee of the American Association for the Study of Liver Diseases addresses all aspects of the practice of liver transplantation.

Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. *JAMA* 1982;247:1164-6.

Centers for Disease Control and Prevention. Alcohol-attributable deaths and years of potential life lost-United States, 2001. *MMWR Morb Mortal Wkly Rep* 2004;53:866-70.

Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. Oct 1 1999;48(RR-12):1-37.

Chalasani N, Aljadhey H, Kesterson J. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology*. May 2004;126(5):1287-92.

Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. *Hepatology*. Apr 2005;41(4):690-5.

Chamuleau RA. Bioartificial liver support anno 2001. *Metab Brain Dis*. 2002;17:485-91

Chan TY, Chan JC, Tomlinson B, Critchley JA. Chinese herbal medicines revisited: a Hong Kong perspective. *Lancet*. Dec 18-25 1993;342(8886-8887):1532-4.

Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. *Arch Pathol Lab Med*. Mar 1999;123(3):251-6.

Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naïve patients. *Hepatology*. 2004;40:193A.

Conn HO, Leevy CM, Vlahcevic ZR, et al (1977). "Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial". *Gastroenterology* 72 (4 Pt 1): 573–83. PMID 14049.

Córdoba J, López-Hellín J, Planas M, et al (2004). "Normal protein diet for episodic hepatic encephalopathy: results of a randomized study". *J. Hepatol.* 41 (1): 38–43. doi:10.1016/j.jhep.2004.03.023. PMID 15246205.

Crawford JM. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, Pa.: Elsevier Saunders, 2005:877-938.

Crawford. The liver and the biliary system. Robbins, Kumar, Cotran. Basic pathology, sixth edition. United States of America, Saunders, 1997.

Cuervas-Mons, A Colas, J. A. Rivera and E. Prados, In vivo efficacy of a bioartificial liver in improving spontaneous recovery from fulminant hepatic failure: a controlled study in pigs. *Transplantation* 69, 2000, (3), 337-344.

Davern Tim (2001). Fulminant hepatic failure. UCSF GI division fellow's Course.

Davern TJ 2nd, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. *Gastroenterology*. Mar 2006;130(3):687-94.

Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. *Hepatology*. Sep 1997;26(3 Suppl 1):122S-127S.

Davis GL. Hepatitis C. In: Schiff ER, Sorrell MJ, Maddrey WC, eds. *Schiff's Diseases of the Liver*. 8th ed. Philadelphia: Lippincott-Raven; 1999:793-836.

Delcker AM, Jalan R, Comes G. L-ornithine-l-aspartate vs. placebo in the treatment of hepatic encephalopathy: a meta-analysis of randomised placebo-controlled trials using individual data. *Hepatology*. 2000;32:310A

Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. *Ann Surg*. May 2004;239(5):660-7; discussion 667-70.

Detry O, Arkadopoulos N, Ting P, Kahaku E, Margulies J, Arnaout W, et al. Intracranial pressure during liver transplantation for fulminant hepatic failure. *Transplantation*. Mar 1999;67(5):767-70.

Diehl A. Alcoholic and nonalcoholic steatohepatitis. Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa.: Saunders, 2004:935-6.

Dienstag JL, Isselbacher KJ. Toxic and Drug-Induced Hepatitis. In: Kasper DL, Braunwald E, Fauci A, Hauser S, Longo D, Jameson JL, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill Professional; 2003:. Chapter 296.

Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med*. Oct 1999;341(17):1256-63.

Dienstag JL, Schiff ER, Wright TL. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis B e-antigen (HBeAg) seroconversion. *Gastroenterol*. 1998;114:A1235.

Dienstag JL. Sexual and perinatal transmission of hepatitis C. *Hepatology*. Sep 1997;26(3 suppl 1):66S-70.

Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. *Clin Chem* 2000;46:2027-49.

Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. *Clin Chem* 2000;46:2050-68.

Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. *N Engl J Med*. Feb 1976;294(9):470-2.

Ellis A, Wendon J. Circulatory, respiratory, cerebral and renal derangements in acute liver failure: Pathophysiology and management. *Semin Liver Dis* 1996; 16: 379-88.

Ellis AJ, Hughes ED, Nicholl D, Langley PO, Wendon JA, O'Grady JG, Williams R. Temporary extrahepatic liver support for severe acute alcoholic hepatitis using the BioLogic-DT. *Int J Artif Organs* 1992; 22: 27-34.

Epstein M. The hepatorenal syndrome--newer perspectives. *N Engl J Med*. Dec 1992;327(25):1810-1.

Ernst E. Safety concerns about kava. *Lancet*. May 2002;359(9320):1865.

Falkenhagen D ,Stroble W,Voget G ,et al . fractioned plasma separation and adsorption system :a novel system for blood purification to remove albumin bound substances . [Art. Organs 1999;23:81-6. Pub Med]

Farmer DG, Anselmo DM, Ghobrial RM, et al: Liver transplantation for fulminant hepatic failure: Experience with more than 200 patients over a 17-year period. *Ann Surg* 2003;237:666-676. Long-term survival was nearly 70%, and the serum creatinine level was the single most important predictor of survival .

Farrell GC. Drug-induced hepatic injury. *J Gastroenterol Hepatol*. Oct 1997;12(9-10):S242-50.

Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A (2002). "Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998". *Hepatology* 35 (3): 716–21. doi:10.1053/jhep.2002.31250. PMID 11870389.

Feverly J, Van Cutsem E, Nevens F, Van Steenberghe W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. *J Hepatol*. Sep 1990;11(2):153-8.

Fischer L, Stemeck M, Rogiers X. Liver transplantation for acute liver failure. *Eur J Gastroenterol Hepatol* 1999; 11: 985-90.

Flendrig LM., la Soc JW., Jorning GGA., Steenbeek A., Ladiges NCJJ., te Velde AA., Chamuleau RAFM. In vitro evaluation of a novel bio-artificial liver system based on a spirally non-woven polyester matrix for high density hepatocyte culture as small aggregates. *J Hepatol*; 1997, 26:1379-1392

Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. *Hepatology*. Dec 1994;20(6):1495-501.

Foutch PG, Sullivan JA, Gaines JA, Sanowski RA. Cutaneous vascular spiders in cirrhotic patients: correlation with hemorrhage from esophageal varices. *Am J Gastroenterol* 1988;83:723-6.

Fried MW, Hoofnagle JH. Therapy of hepatitis C. *Semin Liver Dis.* Feb 1995;15:82-91.

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med.* Sep 26 2002;347(13):975-82.

Friedman SL, Schiano T. Cirrhosis and its sequelae. In: Goldman L, Ausiello D, eds. *Cecil Textbook of medicine*. 22nd ed. Philadelphia, Pa.: Saunders, 2004:936-44

Friedman SL: Molecular regulation of hepatic fibrosis; an integrated cellular response to tissue injury [mini-review]. *J Biol Chem* 2000;275:2247-2250, with permission.)

Fullen WD. Hepatorenal syndrome: reversal by peritoneovenous shunt. *Surgery.* Sep 1977;82(3):337-41.

Gambro Lundia AB (October 2008) .

Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. *Gastroenterology.* Jul 1993;105(1):229-36.

Gines A, Salmeron JM, Gines P, Arroyo V, Jimenez W, Rivera F, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. *J Hepatol.* Feb 1993;17(2):220-6.

Ginès P et al: Management of cirrhosis and ascites. *N Engl J Med* 2004;350:1646.

Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. *Lancet*. Nov 2003;362(9398):1819-27.

Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. *Transplantation*. Feb 1991;51(2):428-30.

Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. *JAMA*. Feb 1995;273(6):489-90.

Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. *Hepatology*. Aug 1998;28(2):416-22.

Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. *Hepatology*. Jan 1998;27(1):35-41.

Guevara M, Ginès P. Hepatorenal syndrome. *Dig Dis*. 2005;23(1):47-55.

Guevara M, Rodes J. Hepatorenal syndrome. *Int J Biochem Cell Biol*. Jan 2005;37(1):22-6.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med*. Feb 27 2003;348(9):800-7.

Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. *N Engl J Med*. Jun 1991;324(26):1852-7.

Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. *Med Clin North Am* 2005;89: 391-409.

Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure. Part II: Complications and treatment. *Am Fam Physician* 2006;74:765-74, 779.
Friedman S, Schiano T. Cirrhosis and its sequelae. In: Goldman L, Ausiello

D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa.: Saunders, 2004:936-44.

Henriksen JH. Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. *J Hepatol.* 1995;23 Suppl 1:25-30.

Heuman DM et al: Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. *Hepatology* 2004;40:802.

Hoeper MM et al: Portopulmonary hypertension and hepatopulmonary syndrome. *Lancet* 2004;363:1461.

Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. *Hepatology.* Jan 1995;21(1):240-52.

Hughes R, Ton HY, Langley P, et al. Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure . Part II: in vivo evaluation. *Artificial organs* [1979;3:23-6 .Pub Med]

Hughes RD, *et al.* Artificial liver support in acute liver failure: A review of studies of King's. *Artif Organs* 1992; 16, 167-70.

Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. *Semin Liver Dis.* Nov 1996;16(4):435-44.

Hughes RE), Pucknell A, Rowley D, Langley PO, X'endon JA, Williams R. Evaluation of the BioLogic-DT sorbent suspension dialyser in patients with fulminant hepatic failure. *Int J Artif Organs.* 1994; 18; 355-62.

Hunt CM, Westerkam WR, Stave GM, Wilson JA. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. *Mech Ageing Dev.* Jun 1992;64(1-2):189-99.

Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. *Biochem Pharmacol.* Jul 22 1992;44(2):275-83.

IJ Beckingham. 2001, ABC OF LIVER, PANCREAS AND GALL BLADDER , CHAPTER 14 , page :47

Ishak KG. Drug-Induced Liver Injury Pathology. In: Clinical and Pathological Correlations in Liver Disease. *American Association for the Study of Liver Disease Post Graduate Course*; . 1998: 236.

Ito K, Mitchell DG, Hann HW, Kim Y, Fujita T, Okazaki H, et al. Viral-induced cirrhosis: grading of severity using MR imaging. *AJR Am J Roentgenol* 1999;173:591-6.

Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med*. Nov 2001;345(20):1452-7.

Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. *Gastroenterology*. Nov 2004;127(5):1338-46.

Jalan R, Williams R. Acute on-chronic liver failure: pathophysiological basis of therapeutic options. *Blood Purif* 2002; 20: 252-261.

Jalan R. Acute liver failure: current management and future prospects. *J Hepatol*. 2005;42 Suppl(1):S115-23.

Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. *J Clin Gastroenterol*. Apr 1990;12(2):203-6.

Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. *Clin Gastroenterol Hepatol*. Feb 2004;2(2):87-106.

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. *Clin Gastroenterol Hepatol*. Aug 2006;4(8):936-62.

keeffe Eb.selection of patients for liver transplantation. in maddrey wc,sorrel me,schiff er.transplantation of liver,philadelphia.lippicott williams&wilkins,2001 pp,5-34 with permission.

Keeffe EB: Liver transplantation: current status and novel approaches to liver replacement. *Gastroenterology* 2001;120:749-762. This review summarizes the current status of liver transplantation, including organ allocation, and concisely reviews the use of split livers and the evolving practice of living donor liver transplantation.

Kelly D A (1997). Acute liver failure. Clinical practice guideline committee, Children's hospital Boston

Kersh ES, Rifkin H (1973). "Lactulose enemas". *Ann. Intern. Med.* **78** (1): 81–4. PMID 4682313.

Kiley JE, Welsh HF, Pender JC, et al. Removal of blood ammonia by hemodialysis. *Proc Soc Exp Biol Med* 1956; 91: 489-490.

Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. *Hepatology*. Jun 1997;25(6):1351-60.

Kiser TH, Fish DN, Obritsch MD, et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. *Nephrol Dial Transplant*. Sep 2005;20(9):1813-20.

Klein AS, Hart J, Brems JJ, Goldstein L, Lewin K, Busuttil RW. Amanita poisoning: treatment and the role of liver transplantation. *Am J Med*. Feb 1989;86(2):187-93.

Kobayashi N, Fujiwara T, Westerman KA, Inoue Y, Sakaguchi M, Noguchi H, et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. *Science*. Feb 18 2000;287(5456):1258-62.

Kramel, Bauer E. Extracorporeal treatment in F.H.F. : Pathophysiologic consideration, [Int J Artificial Organs. 2002; 25: 929-34]

Kramer D, Mazariegos GV, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. *Liver Transpl* 2000; 6: 163-9.

Lake, JR. Liver Transplantation. Friedman SL, McQuaid KR, Grendell JH. Current Diagnosis and Treatment in Gastroenterology. Lange, McGraw-Hill, 2002. Chapter 54.

Laliberte L, Villeneuve JP. Hepatitis after the use of germander, a herbal remedy. *CMAJ*. jun 1996;154(11):1689-92.

Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. *J Hepatol*. 1997;26 Suppl 2:12-21.

Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (*Teucrium chamaedrys*) administration: another instance of herbal medicine hepatotoxicity. *Ann Intern Med*. Jul 1992;117(2):129-32.

Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. *Hepatology*. Dec 2005;42(6):1364-72.

Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. *Hepatology*. Aug 1999;30(2):546-9.

Lau G, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40kD) (Pegasys) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. *Hepatology*. 2004;40:171A.

Lee WM, Denton WT. Chronic hepatitis and indolent cirrhosis due to methyldopa: the bottom of the iceberg?. *J S C Med Assoc*. Feb 1989;85(2):759.

Lee WM, Galbraith RM, Watt GH, Hughes RD, McIntire DD, Hoffman BJ, et al. Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. *Hepatology*. Jan 1995;21(1):101-5.

Lee WM, Schiodt FV. Fulminant hepatic failure. In: Schiff ER, Sorrell MF. *Schiff's Diseases of the Liver*. 8th ed. Baltimore: Lippincott Williams & Wilkins; 1999.

Lee WM. Acute liver failure in the United States. *Semin Liver Dis*. Aug 2003;23(3):217-26.

Lee WM. Acute liver failure. *N Engl J Med*. Dec 1993;329(25):1862-72.

Lee WM. Drug-induced hepatotoxicity. *N Engl J Med*. Jul 31 2003;349(5):474-85.

Lee WM. Drug-induced hepatotoxicity. *N Engl J Med*. Oct 1995;333(17):1118-27.

Lee WM. Drug-induced liver disease. In: Drugdex [online]. Vol 118 (June). Micromedex Healthcare Series;. 1996.

Lee WM. Impact of Drug Induced Liver Toxicity on Hepatology and Practice of Medicine. *US Food and Drug Administration, Center for Drug Evaluation and Research*; 2001. [Full Text].

Lenz K, Druml W, Kleinberger G, Hortnagl H, Laggner A, Schneeweiss B, et al. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. *Gut*. Dec 1985;26(12):1385-6.

Lenz K, Hortnagl H, Druml W, Grimm G, Laggner A, Schneeweisz B, et al. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. *Gut*. Jan 1989;30(1):90-6.

Lenz K, Hortnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. *Gastroenterology*. Oct 1991;101(4):1060-7.

Levy M. Hepatorenal syndrome. *Kidney Int*. Mar 1993;43(3):737-53.

Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients *Hepatology*. May 1989;9(5):679-85.

Lewis JH. Drug-induced liver disease. *Med Clin North Am*. Sep 2000;84(5):1275-311, x. .

Lidofsky SD (1995). Fulminant hepatic failure. *Crit Care Clin*;1 1:415-430

Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. *Hepatology*. Jul 1992;16(1):1-7.

Lidofsky SD. Liver transplantation for fulminant hepatic failure. *Gastroenterol Clin North Am*. Jun 1993;22(2):257-69.

Lok ASF, McMahon BJ. American Association for the Study of Liver Diseases. AASLD practice guideline: chronic hepatitis B. Available at: www.aasld.org. 2003;[Full Text].

Lomas DJ. The liver. In: Grainger RG, Allison DJ, eds. Grainger and Allison's Diagnostic Radiology: A Textbook of Medical Imaging. 4th ed. London, England: Churchill Livingstone, 2001:1247-8.

Lorenzen et al, Medicinsk Compendium, 15. edition, Kobenhavn, Nyt Nordisk Forlag Arnold Busck, 1999,

Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. *Hepatology*. Jan 2001;33(1):123-30.

Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?. *Hepatology*. Feb 1989;9(2):215-8.

Major study: Bioartificial liver reduces mortality by 44 percent in acute liver-failure patients. **2004**

Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM, et al. Reversibility of cirrhosis in chronic hepatitis B. *Clin Gastroenterol Hepatol* 2004;2:344-7.

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*. Sep 2001;358(9286):958-65.

Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med*. Feb 27 2003;348(9):808-16.

Marcellin P, Lau GK, Bonino F, Farci P, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. Dec 30 2004;351(27):2879.

Maroto A, Gines A, Salo J, et al. Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. *Hepatology*. Oct 1994;20(4 Pt 1):839-44.

Matsumura KN, Guevara GR, Huston H, *et al*. Hybrid bioartificial liver in hepatic failure: Preliminary clinical report. *Surgery* 1987; 101: 99-103.

Mays ET, Christopherson W. Hepatic tumors induced by sex steroids. *Semin Liver Dis*. May 1984;4(2):147-57.

McCaughan GW, Huynh JC, Feller R, Painter D, Waugh R, Sheil AG. Fulminant hepatic failure post liver transplantation: clinical syndromes, correlations and outcomes. *Transpl Int*. 1995;8(1):20-6.

McClain CJ, Price S, Barue S, et al. Acetaminophen hepatotoxicity. *Cur Gastroenterol Rep* 1999; 1: 42-9.

McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. *Ann Intern Med*. Feb 1993;118(4):255-67.

McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med*. Nov 1998;339(21):1485-92.

McLaughlin *et al* Overview of Extracorporeal Liver Support Systems and Clinical Results, *Annals New York Academy of Sciences*. 1999 18;875:30-25.

Michalopoulos, GK and DeFrances, MC: Liver regeneration. *Science*, 1997; 276, 4, 60 — 66.

Milhis JM, et al: Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: System modifications and clinical impact.

Mitzner et al Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. *Liver Transpl.* May 2000. 6(3): 287-9.

Mitzner SR, Strange J, Klammt S, et al, Improvement of hepatorenal syndrome with extracorporeal albumin dialysis. *Liver Transpl* 2000;6:277-86.

Monteith DK, Emmerling MR, Garvin J, Theiss JC. Cytotoxicity study of tacrine, structurally and pharmacologically related compounds using rat hepatocytes. *Drug Chem Toxicol.* 1996;19(1-2):71-84.

Morelli S, Guido V, De Marzio P, et al. Early hepatitis during intravenous amiodarone administration. *Cardiology.* 1991;78(3):2914.

Morgan MH, Read AE, Speller DC (1982). "Treatment of hepatic encephalopathy with metronidazole". *Gut* 23 (1): 1-7.
doi:10.1136/gut.23.1.1. PMID 7035298.

Munoz SJ. Different management problems in fulminant hepatic failure. *Semin Liver Dis* 1993; 13: 395A13.

Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. *Am J Gastroenterol.* Jul 1996;91(7):1436

National Center for Health Statistics. National Vital Statistics Report. Chronic liver disease/cirrhosis. Accessed May 2006, at: www.cdc.gov/nchs/fastats/liverdis.htm.

Neff GW et al: Review article: current status of liver transplantation in HIV-infected patients. *Aliment Pharmacol Ther* 2004;20:993.

Neimark E, Schilsky ML, Schneider BL. Wilson's disease and hemochromatosis. *Adolesc Med Clin* 2004;15:175-94, xi.

Neuschwander-Tetri BA. Organ interactions in the hepatorenal syndrome. *New Horiz.* Nov 1994;2(4):527-44.

Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. *Arch Dermatol*. Sep 1989;125(9):1218-24..

Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet*. Oct 1995;346(8982):1051-5.

Nyberg SL, Misra SP. Hepatocyte liver-assist systems--a clinical update. *Mayo Clin Proc*. Aug 1998;73(8):765-71.

O'beirne JP, Heneghan MA. Current management of the hepatorenal syndrome. *Hepatol Res*. Aug 2005;32(4):243-9.

O,Grady J. Personal view :Current role of artificial liver support .[Aliment pharmacol therapy : 2006 jun 1;23 (11) :1549-57 PMID]

O,Grady JG , Gimson AE ,O, Brien CJ , et al , Controlled trials of charcoal Hemoperfusion and prognostic factors in fulminant hepatic failure. *Gastroenterology*[1988;94:1186-92.BubMed]

O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. *Gastroenterology* 1989; 97: 439-45.

O'Grady J. Personal view: current role of artificial liver support devices. *Aliment Pharmacol Ther*. 2006 Jun 1;23(11):1549-57.

O'Grady JG, Alexander GJ, Thick M, Potter D, Calne RY, Williams R. Outcome of orthotopic liver transplantation in the aetiological and clinical variants of acute liver failure. *Q J Med*. Oct 1988;68(258):817-.

O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. *Lancet*. Jul 1993;342(8866):273-5.

O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. *Lancet*. Jul 1993;342(8866):273-5.

Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. *Hepatology*. Oct 2002;36(4 Pt 1):941-8.

Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med.* Dec 2002;137(12):947-54.

Pearlman B, Ehleben C, Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2b plus weight-based ribavirin in a difficult-to-treat population of genotype 1-infected slow responders. *Hepatology.* 2006;44:318A.

Pedretti G, Calzetti C, Missale G, Fiaccadori F (1991). "Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial". *The Italian journal of gastroenterology* **23** (4): 175–8. PMID 1751811.

Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. *Semin Liver Dis.* Nov 1996;16(4):403-14.

Peron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. *Am J Gastroenterol.* Dec 2005;100(12):2702-7.

Pilette C, Oberti F, Aube C, Rousselet MC, Bedossa P, Gallois Y, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. *J Hepatol* 1999;31:867-73.

Pirovino M, Linder R, Boss C, Kochli HP, Mahler F. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. *Klin Wochenschr* 1988;66:298-302.

Pitltin and Mullon, Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. *Artificial organs*, ma 1999, 23(9) 829-833.

Podolsky DK, Isselbacher KJ. Approach to the Patient with Gastrointestinal Disease. Braunwald li, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. *Harrison's Principles of Internal Medicine*, fifteenth edition. McGraw-Hill, 2000. Chapter 282.

Polson J, Lee WM,. AASLD position paper: the management of acute liver failure. *Hepatology*. May 2005;41(5):1179-97.

Poo JL, Góngora J, Sánchez-Avila F, *et al.* (2006). "Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study". *Annals of hepatology : official journal of the Mexican Association of Hepatology* 5 (4): 281–8. PMID 17151582.

Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, *et al.* Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. *Gastroenterology*. May 1984;86(5 Pt 1):926-36.

Poynard T, Leroy V, Cohard M, *et al.* Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. *Hepatology*. Oct 1996;24(4):778-89.

Poynard T, McHutchison J, Davis GL, *et al.* Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. *Hepatology*. Nov 2000;32(5):1131-7.

Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007). "Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy". *Hepatology* 45 (3): 549–59. doi:10.1002/hep.21533. PMID 17326150.

Rahman TM, Hodgson HiP. Clinical management of acute hepatic failure. *Inten Care Med* 2001; 27: 467-76

Rahman TM, Hodgson HIP. Review article: liver support systems in acute liver failure. *Aliment Pharmacol Therapy* 1999; 13: 1255-72

Ratnaik RN, Hicks EP, Hislop IG (1975). "The rectal administration of lactulose". *Australian and New Zealand journal of medicine* 5 (2): 137–40. PMID 240347.

Ridker PM, Ohkuma S, McDermott WV, *et al.* Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. *Gastroenterology*. Apr 1985;88(4):1050-4. .

Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D. Prometheus--a new extracorporeal system for the

treatment of liver failure. *J Hepatol.* 2003 Dec;39(6):984-90. PMID 14642616

Rigas B, Rosenfeld LE, Barwick KW, et al. Amiodarone hepatotoxicity. A clinicopathologic study of five patients. *Ann Intern Med.* Mar 1986;104(3):348-51.

Riordan SM, Williams R. Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. *J Gastroenterol Hepatol* 1999; 14: 757-770.

Roberts LR, Kamath PS. Ascites and hepatorenal syndrome: pathophysiology and management. *Mayo Clin Proc.* Sep 1996;71(9):874-81.

Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, et al. Fungal infection: a common, unrecognised complication of acute liver failure. *J Hepatol.* Jan 1991;12(1):1-9.

Rolando N, Wade JJ, Stangou A, Gimson AE, Wendon J, Philpott-Howard J, et al. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. *Liver Transpl Surg.* Jan 1996;2(1):8-13

Rozga J. Hepatocyte proliferation in health and in liver failure. *Med Sci Monit* 2002; 8(2): 32-8.

Runyon BA: Management of adult patients with ascites due to cirrhosis. *Hepatology* 2004;39:841

Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. *Hepatology.* Feb 1993;17(2):219-24.

Salo J, Gines A, Quer JC, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. *J Hepatol.* Dec 1996;25(6):916-23.

Sass DA, Shakil AO. Fulminant hepatic failure. *Liver Transpl.* Jun 2005;11(6):594-605.

Sauer TM, Gerlach JC: Modular extracorporeal liver support. *Artif Organs* 2002, aug 26 (8); 703-6

Sauer TM, *et al*: Primary human liver cells as source for modular extracorporeal liver support — a preliminary report. *Artif organs* 2002, oct; 25 (10): 1001-5

Schechter DC, Nealon TF, Gibbon JH. A simple extracorporeal device for reducing elevated blood ammonia levels. *Surgery* 1958; 44; 892-897.

Schiødt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. *Liver Transpl Surg* 1999; 5: 86-9.

Schiødt FV, Lee WM. Fulminant liver disease. *Clin Liver Dis*. May 2003;7(2):331-49, vi.

Schiødt FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. *N Engl J Med* 1997; 337: 1112-7.

Schiødt FV, Rossaro L, Stravitz RT, Shakil AO, Chung RT, Lee WM, et al. Gc-globulin and prognosis in acute liver failure. *Liver Transpl*. Oct 2005;11(10):1223-7.

Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. *Hepatology*. Jan 2005;41(1):26-31.

Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. *Liver Int*. 2004;24:2004.

Sechser A, Osorio J, Freise C, et al. Artificial liver support devices for fulminant hepatic failure. *Clin Liver Dis* 2001; 5: 415-30.

Sen S, Jalan R, Williams R. Extracorporeal albumin dialysis in acute — on-chronic liver failure, will it stand the test of time? [*Hepatology* 2002 ;36:1014-16. *Pub Med*]

Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. *Hepatology*. Aug 2002;36(2):451-5.

Shakil AO, Kramer D, Mazariegos GV, Fungj,J, Rakela J. Acute liver failure: Clinical features, outcome analysis, and applicability of prognostic criteria. *Liver transplant* 2000; 6: 163-169.

Shakil AO, Mazariegos GV, Kramer DJ. Fulminant hepatic failure. *Surg Clin North Am*. Feb 1999;79(1):77-108.

Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. *Arch Intern Med*. Apr 28 1997;157(8):913-9.

Sherlock S, Dooley J. Drugs and the Liver. In: Diseases of the Liver and Biliary System. 11th ed. Oxford, England: Blackwell Science; 2002:. 335-64.

Shouval D, Lai C-L, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027. *Hepatology*. 2004;40:728A.

Simonovsky V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. *Br J Radiol* 1999;72:29-34.

Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. *J Hepatol* 2001;35:195-9.

Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. *Lancet*. Jun 1996;347(9018):1842-3.

Sorrentino F. Prime ricerche per la realizzazione di un fegato artificiale. *Ghir Patol Sper* 1956; 4: 1401- 1414.

Stange et al, Albumin dialysis for liver support therapy, *Artif organs*, vol 23, no 4, 1999.

Stange J ,Ram low W, Mitzener S,et al . Anew procedure for the removal of protein bound drugs and toxins .[Asaio J 1993;39: M621-5 .Pub Med]

Stange J, Ram low W ,Mitzener S ,et al . Dialysis against a recycled albumin Solution enables the removal of albumin-bound toxins . Artif. Organs 1993;17:809-13. Pub Med .

Stauch S, Kircheis G, Adler G, *et al* (1998). "Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study". *J. Hepatol.* **28** (5): 856–64. doi:10.1016/S0168-8278(98)80237-7. PMID 9625322.

Steiner Christian, Pezynska-Jolanta Majcher, Piotr Pezynski (April 2002). Therapy informaion for Doctors and Nurses(MARS)

Strange J, Hassanein TI, Mehta R, et al. The molecular absorbents recycling system as a liver support system. *Artif Organs* 2002;26: 103-10.

Strauss G, Hansen BA, Knudsen GM, Larsen FS. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. *Hepatology* 1998; 28: 199-203.

Strauss GI, Knudsen GM, Kondrup J, Moller L, Larsen FS. Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure, *Gastroenterology* 2001; 121: 1109-19.

Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. *Crit Care Med.* Nov 2007;35(11):2498-508.

Sussman NL , Chong MG ,Koussayer T ,et al . Reversal of fulminante hepatic failure [using an extracorporeal liver assist device. *Hepatology* 1992;16:60- 5. Pub Med]

Sussman NL, Chong MG, Koussayir T, He DL, Shong TA, Whisennand HH, KellyJH. Reversal of fulminant hepatic failure using an extracorporeal liver assist device, *Hepatology* 1992; 16: 60-65.

Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. *Artif Organs*. May 1994;18(5):390-6.

Tabor E. The role of tumor suppressor genes in the development of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. *Liver Cancer*. New York: Churchill Livingstone; 1997:89-95.

Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. *Annu Rev Pharmacol Toxicol*. 1998;38:389-430.

Tinsly RHarrison's. Principles of Internal Medicine, sixteen edition ,chapter:291,page:1873 ,2005

Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. *Hepatology*. Sep 1997;26(3):747-54.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*. Jul 29 2004;351(5):438-50.

Trey C, Davidson CS. The mangement of fulminant hepatic failure. *Prog Liver Dis* 1970; 3: 282-98.

Trey C. The fulminant hepatic failure surveillance study. Brief review of the effects of presumed etiology and age on survival. *CMAJ*, 1972; 106.

Ttewbv PN, Williams R. Pathophysiology of hypotension in patient with fulminant hepatic failure. *Gut* 1977; 18:1021-1026,

United Network for Organ Sharing. Data. Accessed May 2006, at: www.unos.org/data/.

Uribe M, Campollo O, Vargas F, *et al* (1987). "Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial". *Hepatology* 7 (4): 639–43. doi:10.1002/hep.1840070404. PMID 3301614.

Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. *Gastroenterology*. Apr 1986;90(4):807-11.

Van de Kerkhove, Di Florio E, Scuderi V *et al*. Phase I clinical trial with the AMCBioartificial liver. *Artif Organs* 2002; 25:950-959.

49. Chamuleau RA. Bioartificial liver support anno 2001. *Metab Brain Dis*. 2002; 17: 485-91.

Van Roey G, Moore K. The hepatorenal syndrome. *Pediatr Nephrol*. Feb 1996;10(1):100-7.

Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J Med*. Jan 29 1998;338(5):286-90.

Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. *Am J Med Sci*. Feb 2005;329(2):62-5.

Wang-Lischeng *et al*; Cell-Transplantation 1998: 7(5): 459-468

Watanabe FE), et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. *Ann Surg*. 1997 May;225(5):484-91; discussion 491-4

Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. *Hepatology*. Mar 2006;43(3):618-31.

Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. *JAMA*. Apr 1994;271(13):992-8.

Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. *Ann Intern Med*. Nov 1984;101(5):613-6.

Wendon JA, Harrison PM, Keays R, Gimson AR, Alexander GJ, Williams R. Effects of vasopressor agents and epoprostenol on systemic hemodynamics and oxygen transport in fulminant hepatic failure.

Hepatology 1992; 15: 1067-71.

Wiesner RH, McDiarmid SV, Kamath PS, et al: MELD and PELD: application of survival models to liver allocation. *Liver Transpl* 2001;7:567-580. This review outlines the rationale and logistics of the Model for End-Stage Liver Disease and how it will impact the organ allocation system in the United States.

Wilkinson AH et al. Hemodiabsorption in treatment of hepatic failure with coma; results of a randomized, controlled study. *Journal of Transpl Coord.* 1998; 8; 43-50.

Williams R, James OF, Warnes TW, Morgan MY (2000). "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study". *European journal of gastroenterology & hepatology* 12 (2): 203–8. PMID 10741936.

Witzke O, Baumann M, Patschan D, et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome?. *J Gastroenterol Hepatol.* Dec 2004;19(12):1369-73.

Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. *Ann Intern Med.* Aug 1993;119(4):312-23.

Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. *Hepatology.* Jul 2004;40(1):55-64.

Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol.* 1992;22(1):1-21.

Yee HF, Lidofsky SD. Acute liver failure. In: Feldman M, Friedman LS, Sleisenger MH, eds. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management.* 7th ed. Philadelphia, Pa.: Saunders, 2002:1567-74.

Zafrani ES, von Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. *Arch Intern Med.* Mar 1983;143(3):495-502.